Liver Toxicity with Cancer Checkpoint Inhibitor Therapy

 

 Buy Article Permissions and Reprints

Abstract

Immune checkpoint inhibition targeted against cytotoxic T-lymphocyte–associated antigen 4 (CTLA-4) and programmed cell death protein 1 (PD-1) has shown clinically significant survival benefit when used to treat multiple types of advanced cancer. These drugs have gained approval by the US Food and Drug Administration and their indications continue to increase. Checkpoint inhibitor therapy is associated with a unique side-effect profile characterized as immune-related adverse events (irAEs), which can result in significant morbidity and rarely mortality. Hepatotoxicity from checkpoint inhibitors is a less common irAE and often mild, while its incidence and severity vary based on the class and dose of checkpoint inhibitor, monotherapy versus combination therapy, and the type of cancer. Histological assessment of suspected irAEs is nonspecific and can show a variety of features. Hepatic irAEs can require discontinuation of checkpoint inhibitor therapy and treatment with immunosuppressive agents.

• References

• 1 Kohler BA, Sherman RL, Howlader N. , et al. Annual Report to the Nation on the Status of Cancer, 1975–2011, Featuring Incidence of Breast Cancer Subtypes by Race/Ethnicity, Poverty, and State. J Natl Cancer Inst 2015; 107 (06) djv048
  PubMedGoogle Scholar
• 2 Mellman I, Coukos G, Dranoff G. Cancer immunotherapy comes of age. Nature 2011; 480 (7378): 480-489
  CrossrefPubMedGoogle Scholar
• 3 Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med 2018; 378 (02) 158-168
  CrossrefPubMedGoogle Scholar
• 4 Vivier E, Malissen B. Innate and adaptive immunity: specificities and signaling hierarchies revisited. Nat Immunol 2005; 6 (01) 17-21
  CrossrefPubMedGoogle Scholar
• 5 Wang M, Yin B, Wang HY, Wang RF. Current advances in T-cell-based cancer immunotherapy. Immunotherapy 2014; 6 (12) 1265-1278
  CrossrefPubMedGoogle Scholar
• 6 Topalian SL, Hodi FS, Brahmer JR. , et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012; 366 (26) 2443-2454
  CrossrefPubMedGoogle Scholar
• 7 Zamarin D, Postow MA. Immune checkpoint modulation: rational design of combination strategies. Pharmacol Ther 2015; 150: 23-32
  CrossrefPubMedGoogle Scholar
• 8 Buchbinder EI, Desai A. CTLA-4 and PD-1 pathways: similarities, differences, and implications of their inhibition. Am J Clin Oncol 2016; 39 (01) 98-106
  CrossrefPubMedGoogle Scholar
• 9 Ishida Y, Agata Y, Shibahara K, Honjo T. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J 1992; 11 (11) 3887-3895
  PubMedGoogle Scholar
• 10 Freeman GJ, Long AJ, Iwai Y. , et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 2000; 192 (07) 1027-1034
  CrossrefPubMedGoogle Scholar
• 11 Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 2008; 26: 677-704
  CrossrefPubMedGoogle Scholar
• 12 Okazaki T, Honjo T. PD-1 and PD-1 ligands: from discovery to clinical application. Int Immunol 2007; 19 (07) 813-824
  CrossrefPubMedGoogle Scholar
• 13 Sun Z, Fourcade J, Pagliano O. , et al. IL10 and PD-1 cooperate to limit the activity of tumor-specific CD8+ T cells. Cancer Res 2015; 75 (08) 1635-1644
  CrossrefPubMedGoogle Scholar
• 14 Zou W, Chen L. Inhibitory B7-family molecules in the tumour microenvironment. Nat Rev Immunol 2008; 8 (06) 467-477
  CrossrefPubMedGoogle Scholar
• 15 Brown JA, Dorfman DM, Ma FR. , et al. Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production. J Immunol 2003; 170 (03) 1257-1266
  CrossrefPubMedGoogle Scholar
• 16 Konishi J, Yamazaki K, Azuma M, Kinoshita I, Dosaka-Akita H, Nishimura M. B7-H1 expression on non-small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression. Clin Cancer Res 2004; 10 (15) 5094-5100
  CrossrefPubMedGoogle Scholar
• 17 Dong H, Strome SE, Salomao DR. , et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 2002; 8 (08) 793-800
  CrossrefPubMedGoogle Scholar
• 18 Hodi FS, O'Day SJ, McDermott DF. , et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363 (08) 711-723
  CrossrefPubMedGoogle Scholar
• 19 Institute NC. FDA approval for ipilimumab. 2011 https://www.cancer.gov/about-cancer/treatment/drugs/fda-ipilimumab . Accessed May 17, 2018
  PubMedGoogle Scholar
• 20 Institute NC. FDA approval for pembrolizumab. 2014 https://www.cancer.gov/about-cancer/treatment/drugs/fda-pembrolizumab . Accessed May 17, 2018
  PubMedGoogle Scholar
• 21 Hazarika M, Chuk MK, Theoret MR. , et al. U.S. FDA approval summary: nivolumab for treatment of unresectable or metastatic melanoma following progression on ipilimumab. Clin Cancer Res 2017; 23 (14) 3484-3488
  CrossrefPubMedGoogle Scholar
• 22 Ribas A, Wolchok JD, Robert C. , et al. Updated clinical efficacy of the anti-PD-1 monoclonal antibody pembrolizumab in 411 patients with melanoma. Pigment Cell Melanoma Res 2014; 27 (06) 1222-1223
  PubMedGoogle Scholar
• 23 Robert C, Ribas A, Wolchok JD. , et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet 2014; 384 (9948): 1109-1117
  CrossrefPubMedGoogle Scholar
• 24 Weber JS, D'Angelo SP, Minor D. , et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol 2015; 16 (04) 375-384
  CrossrefPubMedGoogle Scholar
• 25 Larkin J, Minor D, D'Angelo S. , et al. Overall survival in patients with advanced melanoma who received nivolumab versus investigator's choice chemotherapy in CheckMate 037: a randomized, controlled, open-label phase III trial. J Clin Oncol 2018; 36 (04) 383-390
  CrossrefPubMedGoogle Scholar
• 26 Larkin J, Hodi FS, Wolchok JD. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 2015; 373 (13) 1270-1271
  CrossrefPubMedGoogle Scholar
• 27 Motzer RJ, Tannir NM, McDermott DF. , et al; CheckMate 214 Investigators. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N Engl J Med 2018; 378 (14) 1277-1290
  CrossrefPubMedGoogle Scholar
• 28 National Cancer Institute. Common Terminology Criteria for Adverse Events v 4.03. 2009 ;#09–7473.
  PubMedGoogle Scholar
• 29 Fontana RJ, Watkins PB, Bonkovsky HL. , et al; DILIN Study Group. Drug-Induced Liver Injury Network (DILIN) prospective study: rationale, design and conduct. Drug Saf 2009; 32 (01) 55-68
  CrossrefPubMedGoogle Scholar
• 30 Hayashi PH. Drug-induced liver injury network causality assessment: criteria and experience in the United States. Int J Mol Sci 2016; 17 (02) 201
  CrossrefPubMedGoogle Scholar
• 31 Health NIo. Severity grading in drug induced liver injury. 2017 . Available at: https://livertox.nih.gov/Severity.html . Accessed May 19, 2018.
  PubMedGoogle Scholar
• 32 Reuben A. Hy's law. Hepatology 2004; 39 (02) 574-578
  CrossrefPubMedGoogle Scholar
• 33 Regev A, Björnsson ES. Drug-induced liver injury: morbidity, mortality, and Hy's law. Gastroenterology 2014; 147 (01) 20-24
  CrossrefPubMedGoogle Scholar
• 34 O'Day SJ, Maio M, Chiarion-Sileni V. , et al. Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study. Ann Oncol 2010; 21 (08) 1712-1717
  CrossrefPubMedGoogle Scholar
• 35 Fecher LA, Agarwala SS, Hodi FS, Weber JS. Ipilimumab and its toxicities: a multidisciplinary approach. Oncologist 2013; 18 (06) 733-743
  CrossrefPubMedGoogle Scholar
• 36 Wolchok JD, Neyns B, Linette G. , et al. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol 2010; 11 (02) 155-164
  CrossrefPubMedGoogle Scholar
• 37 Eggermont AM, Chiarion-Sileni V, Grob JJ. , et al. Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy. N Engl J Med 2016; 375 (19) 1845-1855
  CrossrefPubMedGoogle Scholar
• 38 Weber JS, Kähler KC, Hauschild A. Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol 2012; 30 (21) 2691-2697
  CrossrefPubMedGoogle Scholar
• 39 Sanjeevaiah A, Kerr T, Beg MS. Approach and management of checkpoint inhibitor-related immune hepatitis. J Gastrointest Oncol 2018; 9 (01) 220-224
  CrossrefPubMedGoogle Scholar
• 40 Robert C, Thomas L, Bondarenko I. , et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011; 364 (26) 2517-2526
  CrossrefPubMedGoogle Scholar
• 41 Weber JS, Postow M, Lao CD, Schadendorf D. Management of adverse events following treatment with anti-programmed death-1 agents. Oncologist 2016; 21 (10) 1230-1240
  CrossrefPubMedGoogle Scholar
• 42 Ascierto PA, Del Vecchio M, Robert C. , et al. Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol 2017; 18 (05) 611-622
  CrossrefPubMedGoogle Scholar
• 43 Naidoo J, Page DB, Li BT. , et al. Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. Ann Oncol 2015; 26 (12) 2375-2391
  CrossrefPubMedGoogle Scholar
• 44 Motzer RJ, Rini BI, McDermott DF. , et al. Nivolumab for metastatic renal cell carcinoma (mRCC): results of a randomized, dose-ranging phase II trial. J Clin Oncol 2014; 33 (13) 1430-1437
  PubMedGoogle Scholar
• 45 Hamid O, Robert C, Daud A. , et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 2013; 369 (02) 134-144
  PubMedGoogle Scholar
• 46 Wolchok JD, Kluger H, Callahan MK. , et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 2013; 369 (02) 122-133
  CrossrefPubMedGoogle Scholar
• 47 El-Khoueiry AB, Sangro B, Yau T. , et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet 2017; 389 (10088): 2492-2502
  CrossrefPubMedGoogle Scholar
• 48 Eigentler TK, Hassel JC, Berking C. , et al. Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy. Cancer Treat Rev 2016; 45: 7-18
  CrossrefPubMedGoogle Scholar
• 49 Herbst RS, Baas P, Kim DW. , et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non–small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 2016; 387 (10027): 1540-1550
  CrossrefPubMedGoogle Scholar
• 50 Sznol M, Ferrucci PF, Hogg D. , et al. Pooled analysis safety profile of nivolumab and ipilimumab combination therapy in patients with advanced melanoma. J Clin Oncol 2017; 35 (34) 3815-3822
  CrossrefPubMedGoogle Scholar
• 51 Ravi S, Spencer K, Ruisi M. , et al. Ipilimumab administration for advanced melanoma in patients with pre-existing hepatitis B or C infection: a multicenter, retrospective case series. J Immunother Cancer 2014; 2 (01) 33
  CrossrefPubMedGoogle Scholar
• 52 Minter S, Willner I, Shirai K. Ipilimumab-induced hepatitis C viral suppression. J Clin Oncol 2013; 31 (19) e307-e308
  CrossrefPubMedGoogle Scholar
• 53 Sharma A, Thompson JA, Repaka A, Mehnert JM. Ipilimumab administration in patients with advanced melanoma and hepatitis B and C. J Clin Oncol 2013; 31 (21) e370-e372
  CrossrefPubMedGoogle Scholar
• 54 Davar D, Wilson M, Pruckner C, Kirkwood JM. PD-1 blockade in advanced melanoma in patients with hepatitis C and/or HIV. Case Rep Oncol Med 2015; 2015: 737389
  PubMedGoogle Scholar
• 55 Wen X, Wang Y, Ding Y. , et al. Safety of immune checkpoint inhibitors in Chinese patients with melanoma. Melanoma Res 2016; 26 (03) 284-289
  CrossrefPubMedGoogle Scholar
• 56 Sangro B, Gomez-Martin C, de la Mata M. , et al. A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C. J Hepatol 2013; 59 (01) 81-88
  CrossrefPubMedGoogle Scholar
• 57 Brown ZJ, Heinrich B, Steinberg SM, Yu SJ, Greten TF. Safety in treatment of hepatocellular carcinoma with immune checkpoint inhibitors as compared to melanoma and non-small cell lung cancer. J Immunother Cancer 2017; 5 (01) 93
  CrossrefPubMedGoogle Scholar
• 58 Champiat S, Lambotte O, Barreau E. , et al. Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper. Ann Oncol 2016; 27 (04) 559-574
  CrossrefPubMedGoogle Scholar
• 59 Brahmer JR, Lacchetti C, Schneider BJ. , et al; National Comprehensive Cancer Network. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 2018; 36 (17) 1714-1768
  CrossrefPubMedGoogle Scholar
• 60 Puzanov I, Diab A, Abdallah K. , et al; Society for Immunotherapy of Cancer Toxicity Management Working Group. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. J Immunother Cancer 2017; 5 (01) 95
  CrossrefPubMedGoogle Scholar
• 61 Kleiner DE, Berman D. Pathologic changes in ipilimumab-related hepatitis in patients with metastatic melanoma. Dig Dis Sci 2012; 57 (08) 2233-2240
  CrossrefPubMedGoogle Scholar
• 62 Ipilimumab (Yervoy) [package insert]. Princeton, NJ: Bristol-Myers Squibb Company; 2011
  Google Scholar
• 63 Nivolumab (Opdivo) [package insert]. Princeton, NJ: Bristol-Myers Squibb Company; 2014
  Google Scholar
• 64 Pembrolizumab (Keytruda) [package insert]. Whitehouse Station, NJ: Merck Sharp & Dohme Corp; 2014
  Google Scholar
• 65 Gutzmer R, Koop A, Meier F. , et al; German Dermatooncology Group (DeCOG). Programmed cell death protein-1 (PD-1) inhibitor therapy in patients with advanced melanoma and preexisting autoimmunity or ipilimumab-triggered autoimmunity. Eur J Cancer 2017; 75: 24-32
  CrossrefPubMedGoogle Scholar
• 66 Johnson DB, Sullivan RJ, Ott PA. , et al. Ipilimumab therapy in patients with advanced melanoma and preexisting autoimmune disorders. JAMA Oncol 2016; 2 (02) 234-240
  CrossrefPubMedGoogle Scholar
• 67 Menzies AM, Johnson DB, Ramanujam S. , et al. Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab. Ann Oncol 2017; 28 (02) 368-376
  CrossrefPubMedGoogle Scholar
• 68 Bostwick AD, Salama AK, Hanks BA. Rapid complete response of metastatic melanoma in a patient undergoing ipilimumab immunotherapy in the setting of active ulcerative colitis. J Immunother Cancer 2015; 3: 19
  CrossrefPubMedGoogle Scholar
• 69 Pedersen M, Andersen R, Nørgaard P. , et al. Successful treatment with Ipilimumab and Interleukin-2 in two patients with metastatic melanoma and systemic autoimmune disease. Cancer Immunol Immunother 2014; 63 (12) 1341-1346
  CrossrefPubMedGoogle Scholar
• 70 Kyi C, Carvajal RD, Wolchok JD, Postow MA. Ipilimumab in patients with melanoma and autoimmune disease. J Immunother Cancer 2014; 2 (01) 35
  CrossrefPubMedGoogle Scholar
• 71 De Martin E, Michot JM, Papouin B. , et al. Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors. J Hepatol 2018; 68 (06) 1181-1190
  CrossrefPubMedGoogle Scholar
• 72 Kim KW, Ramaiya NH, Krajewski KM. , et al. Ipilimumab associated hepatitis: imaging and clinicopathologic findings. Invest New Drugs 2013; 31 (04) 1071-1077
  CrossrefPubMedGoogle Scholar
• 73 Manns MP, Czaja AJ, Gorham JD. , et al; American Association for the Study of Liver Diseases. Diagnosis and management of autoimmune hepatitis. Hepatology 2010; 51 (06) 2193-2213
  CrossrefPubMedGoogle Scholar
• 74 Suzuki A, Brunt EM, Kleiner DE. , et al. The use of liver biopsy evaluation in discrimination of idiopathic autoimmune hepatitis versus drug-induced liver injury. Hepatology 2011; 54 (03) 931-939
  CrossrefPubMedGoogle Scholar
• 75 Villadolid J, Amin A. Immune checkpoint inhibitors in clinical practice: update on management of immune-related toxicities. Transl Lung Cancer Res 2015; 4 (05) 560-575
  PubMedGoogle Scholar
• 76 Everett J, Srivastava A, Misdraji J. Fibrin ring granulomas in checkpoint inhibitor-induced hepatitis. Am J Surg Pathol 2017; 41 (01) 134-137
  CrossrefPubMedGoogle Scholar
• 77 Zen Y, Yeh MM. Hepatotoxicity of immune checkpoint inhibitors: a histology study of seven cases in comparison with autoimmune hepatitis and idiosyncratic drug-induced liver injury. Mod Pathol 2018
  PubMedGoogle Scholar
• 78 Ishak K, Baptista A, Bianchi L. , et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995; 22 (06) 696-699
  CrossrefPubMedGoogle Scholar
• 79 Schadendorf D, Wolchok JD, Hodi FS. , et al. Efficacy and safety outcomes in patients with advanced melanoma who discontinued treatment with nivolumab and ipilimumab because of adverse events: a pooled analysis of randomized phase II and III trials. J Clin Oncol 2017; 35 (34) 3807-3814
  CrossrefPubMedGoogle Scholar
• 80 Carlino MS, Sandhu S. Safety and efficacy implications of discontinuing combination ipilimumab and nivolumab in advanced melanoma. J Clin Oncol 2017; 35 (34) 3792-3793
  CrossrefPubMedGoogle Scholar
• 81 Haanen JBAG, Carbonnel F, Robert C. , et al; ESMO Guidelines Committee. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2017; 28 (04) (Suppl. 04) iv119-iv142
  CrossrefPubMedGoogle Scholar
• 82 Huffman BM, Kottschade LA, Kamath PS, Markovic SN. Hepatotoxicity after immune checkpoint inhibitor therapy in melanoma: natural progression and management. Am J Clin Oncol 2017; (e-pub ahead of print) DOI: 10.1097/COC.0000000000000374.
  CrossrefPubMedGoogle Scholar
• 83 Linardou H, Gogas H. Toxicity management of immunotherapy for patients with metastatic melanoma. Ann Transl Med 2016; 4 (14) 272
  CrossrefPubMedGoogle Scholar
• 84 Friedman CF, Proverbs-Singh TA, Postow MA. Treatment of the immune-related adverse effects of immune checkpoint inhibitors: a review. JAMA Oncol 2016; 2 (10) 1346-1353
  CrossrefPubMedGoogle Scholar
• 85 Lemech C, Arkenau HT. Novel treatments for metastatic cutaneous melanoma and the management of emergent toxicities. Clin Med Insights Oncol 2012; 6: 53-66
  PubMedGoogle Scholar
• 86 Chmiel KD, Suan D, Liddle C. , et al. Resolution of severe ipilimumab-induced hepatitis after antithymocyte globulin therapy. J Clin Oncol 2011; 29 (09) e237-e240
  CrossrefPubMedGoogle Scholar
• 87 McGuire HM, Shklovskaya E, Edwards J. , et al. Anti-PD-1-induced high-grade hepatitis associated with corticosteroid-resistant T cells: a case report. Cancer Immunol Immunother 2018; 67 (04) 563-573
  CrossrefPubMedGoogle Scholar
• 88 Pollack MH, Betof A, Dearden H. , et al. Safety of resuming anti-PD-1 in patients with immune-related adverse events (irAEs) during combined anti-CTLA-4 and anti-PD1 in metastatic melanoma. Ann Oncol 2018; 29 (01) 250-255
  CrossrefPubMedGoogle Scholar
• 89 Weber J, Gibney G, Kudchadkar R. , et al. Phase I/II study of metastatic melanoma patients treated with nivolumab who had progressed after ipilimumab. Cancer Immunol Res 2016; 4 (04) 345-353
  CrossrefPubMedGoogle Scholar